Menu Search
Equities

Psyence Biomedical Ltd

PBM:NMQ

Psyence Biomedical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.0562
  • Today's Change-0.014 / -19.60%
  • Shares traded6.31m
  • 1 Year change-99.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

SmartText is unavailable
Gross margin--
Net profit margin--
Operating margin--
Return on assets1.13%
Return on equity1.27%
Return on investment1.20%
More ▼

Cash flow in USDView more

In 2022, cash reserves at Psyence Biomedical Ltd fell by 519.60k. Cash Flow from Financing was even, which indicates that this company's capital needs are balanced. In addition the company used 519.60k for operations while cash used for investing totalled .
Cash flow per share0.0839
Price/Cash flow per share1.85
Book value per share-0.3979
Tangible book value per share-0.3979
More ▼

Balance sheet in USDView more

Psyence Biomedical Ltd uses little or no debt in its capital structure.
Current ratio0.01
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -2.63%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.